"Most real time qPCR-based assays target only two or three targets on the viral genome." "The MassARRAY SARS-CoV-2 Panel is the only assay on the market with 5 viral genome targets multiplexed into a single reaction, making it robust against potential mutations arising in the viral genome," said Dr. Darryl Irwin, Vice President of Scientific Affairs.
The single-reaction panel targets five regions of the viral genome and provides excellent accuracy and sensitivity.
The MassARRAY System is the perfect tool for that." "To address the crisis presented by COVID-19, labs need to cost-effectively process large numbers of samples. "Agena is proud to offer a truly scalable platform to support the increasing demand for high-throughput SARS-CoV-2 testing," said Peter Dansky, CEO of Agena Bioscience. Food and Drug Administration (FDA).Ĭlinical laboratories can process thousands of samples each day for less than $10 per sample running the assay on a single MassARRAY instrument, making it one of the highest throughput SARS-CoV-2 tests available under the Emergency Use Authorization program. Agena Bioscience, a global provider of low-cost and high-throughput molecular testing solutions, announced its MassARRAY SARS-CoV-2 Panel for qualitative detection of the SARS-CoV-2 coronavirus has been granted Emergency Use Authorization from the U.S.
0 kommentar(er)
